BRAF and hepatocellular carcinoma: In addition, attention should be drawn to the issue that in cells with wild-type BRAF, RAF inhibitors may transactivate ERK signaling resulting in toxicity and drug resistance.218 The low occurrence of BRAF V600 mutations in HCC targeted by vemurafenib, dabrafenib, and encorafenib also limits their application value.